The clinical efficacy of different doses Methimazole treating for Graves' disease and their estrogen levels changes
Objective To observe clinical efficacy of the different doses of Methimazole for the treatment of Graves' disease, study the estrogen levels changes before and after treatment. Methods 56 cases were randomly divided into the low-dose group(15mg/d. once) and conventional-dose group (30mg/d, three times a service), 28 cases in each group. The clinical efficacy and side effects were observed after treating 3 months, Leukemia count, transaminases(ALT, AST) levels of thyroid hormones(FT3, FT4), thyrotropin releasing hormone(TSH) and estrogen(E2) level were detected before treatment and after 3 months, Withdrawal after of 18-24 months, two-year recurrence rate were followed up. Results After 3 months of treatment, the clinical efficacy was no significant difference(P >0.05). FT3, FT4, TSH and E2 level was significantly decreased(P <0.05), Incidence of side effects of the low-dose group compared with conventional dose group was significantly decreased(P <0.05), and follow-up the recurrence rate of the two groups was no difference(P >0.05). Conclusion Low dose of Methimazole can reduce the incidence of side effects in the treatment of Graves' disease, estrogen with Graves' disease has a certain relevance.
NETL
NSTL
万方数据
维普
